- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Torrent Pharma posts net profit of Rs 314 cr for March quarter; revenue up 5 to Rs 1,946 cr
New Delhi: Drug firm Torrent Pharmaceuticals on Tuesday reported a consolidated net profit of Rs 314 crore for the quarter ended 31 March1, mainly on account of cost control and productivity improvements.
The company had posted a net loss of Rs 152 crore for the corresponding period of the previous financial year, Torrent Pharma said in a filing to the BSE.
Its consolidated revenue from operations stood at Rs 1,946 crore for the quarter under consideration as against Rs 1,856 crore for the corresponding period a year ago, it added.
For the financial year ended March this year, the net profit of the company was at Rs 1,025 crore. It was Rs 436 crore for the previous fiscal year, Torrent Pharma said.
The company posted Rs 7,939 crore as revenue from operations for the fiscal year ended March 2020. It was Rs 7,673 crore for the year-ago fiscal year, it added.
"Our fourth-quarter margins continued to benefit largely from the synergies of the acquired Unichem portfolio, incremental productivity and cost control. Our focus continues to remain on India, US, Brazil and Germany as our core markets," Torrent Pharmaceuticals Executive Chairman Samir Mehta said.
For the US, remediation work at Dahej and Indrad has progressed as per plan and the company expects Germany growth to revive in 2020-21, he added.
During these unprecedented times of the pandemic, Torrent Pharma recognises that it has an important role to play in the healthcare ecosystem and has proactively taken actions to ensure product availability and business continuity, Mehta said.
In the fourth quarter, the company announced an interim dividend for 2019-20 of Rs 32 per equity share (including Rs 15 per equity share as a special dividend), which was paid in March 2020. In view of the same, the Board has not considered any further dividends for 2019-20, the filing said.
Shares of Torrent Pharmaceuticals closed at Rs 2,576.65 per scrip on the BSE, down 0.89 percent from its previous close.
Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email:Â editorial@medicaldialogues.in. Contact no. 011-43720751